3D-printed implant maker Restor3d announced today that it completed a funding round, bringing in proceeds totaling $38 million.
Durham, North Carolina-based Restor3d received funds from both existing and new private investors, including Summers Value Partners. It plans to use the money to fuel its continued growth and launch four new 3D-printed product lines in 2025 and 2026. The company said that it continues to approach positive operating cash flow, too. This positions it to continue reinvesting in innovation and expansion while maintaining financial stability.
The new product lines set to be supported by the new funds include the Veritas, iTotal Identity, Kinos and Velora implant offerings. Veritas, a reverse total shoulder system, introduces a single-tray instrument system. It makes patient-specific implants accessible to a wider shoulder patient population. The system still awaits FDA 510(k) clearance.
Restor3d also plans to use funds to support iTotal Identity, its fully cementless, patient-specific porous cementless total knee. The FDA-cleared iTotal Identity delivers optimal coverage and precise alignment while eliminating intraoperative guesswork. Kinos, a total ankle system delivered through an anterior approach, also has FDA clearance.
Finally, Velora, a next-generation 3DP porous acetabular system, promotes osseointegration by incorporating Tidal technology and long-term stability in hip arthroplasty procedures. That system also awaits FDA 510(k) clearance.
“By leveraging advanced 3D printing and AI-driven design, we are restoring mobility and improving lives—whether its helping patients return to work, get back on the golf course, or simply walk without pain,” said Kurt Jacobus, CEO and co-founder. “This funding allows us to further scale our technology, expand access to truly personalized care, and continue setting new standards in orthopedic treatment. We are redefining what’s possible in orthopedics to better serve our surgeons and patients.”
